论文部分内容阅读
目的:研究抗痨合剂对初治肺结核患者CD4+CD25+调节性T细胞及Foxp3的影响。方法:将64例初治肺结核患者随机分中药组和对照组,中药组采用2HRZE/4HR+口服抗痨合剂方案抗结核治疗,对照组采用2HRZE/4HR+口服中药安慰剂方案抗结核治疗,6个月后观察临床疗效,并采用流式细胞术检测各组患者外周血CD4+CD25+Treg细胞的含量,实时荧光定量PCR检测各组患者外周血Foxp3 mRNA的表达。结果:抗痨合剂可显著改善初治肺结核患者咳嗽、咳痰、潮热盗汗、恶心、乏力等临床症状。抗痨合剂可显著减少初治肺结核患者外周血中CD4+CD25+Treg细胞数量,并下调Foxp3 mRNA表达,与对照组比较有统计学意义(P<0.05)。结论:抗痨合剂的作用机制可能是通过减少CD4+CD25+Treg细胞数量、下调Foxp3 mRNA表达,调节机体免疫功能,发挥临床疗效。
Objective: To study the effect of anti-tuberculosis compound on CD4 + CD25 + regulatory T cells and Foxp3 in patients with newly diagnosed pulmonary tuberculosis. Methods: 64 cases of newly diagnosed pulmonary tuberculosis patients were randomly divided into the control group and the traditional Chinese medicine group. The Chinese herb group received anti-tuberculosis treatment with 2HRZE / 4HR + oral anti-tuberculosis agent. The control group received anti-tuberculosis treatment with oral Chinese herbal placebo for 6 months The clinical efficacy was observed. The levels of CD4 + CD25 + Treg cells in peripheral blood were detected by flow cytometry. The expression of Foxp3 mRNA in peripheral blood was detected by real-time fluorescence quantitative PCR. Results: Anti-inflammatory mixture can significantly improve the first-onset pulmonary tuberculosis cough, sputum, hot flashes sweating, nausea, fatigue and other clinical symptoms. Anti-Qi mixture can significantly reduce the number of CD4 + CD25 + Treg cells in peripheral blood of patients with newly diagnosed pulmonary tuberculosis and down-regulate the expression of Foxp3 mRNA, which is statistically significant compared with the control group (P <0.05). Conclusion: The mechanism of anti-tumor mixture may be through reducing the number of CD4 + CD25 + Treg cells, down-Foxp3 mRNA expression, regulate immune function and exert clinical efficacy.